Approved GLP-1 RAs: Indications and Administration Dulaglutide (Trulicity) (injection weekly) Type 2 Diabetes Exenatide extended-release (Bydureon bcise) (injection weekly) Type 2 Diabetes Exenatide (Byetta) (injection twice daily) Type 2 Diabetes Semaglutide (Ozempic) (injection weekly) Type 2 Diabetes Liraglutide (Victoza, Saxenda) (injection daily) Obesity and Type 2 Diabetes, Respectively Lixisenatide (Adlyxin) (injection daily) Type 2 Diabetes Semaglutide (Rybelsus) (taken by mouth once daily) Obesity Semaglutide (Wegovy) (injection weekly) Obesity Tirzepatide* (Mounjaro, Zepbound)(injection weekly) Type 2 Diabetes and Obesity, Respectively View the FDAs up-to-date list of approved GLP-1 RAs Cardiovascular Risk Reduction Benefits of GLP-1 RAs for Patients with T2D 2 to 4 times more likely to develop cardiovascular disease (CVD) than those without T2D
Practical considerations include keeping the peptides in separate vials
This -glutamylated sulfide compound is further deglutamylated and S -oxygenated to yield S -alk(en)yl-L-cysteine sulfoxide ( Figure 1 )
The modifications to the PPS network included both additions of partners to the network or the removal of network partners
Metformin Comparing Adherence Data Prime Therapeutics conducted an analysis of 4,066 commercially insured obese, non-diabetic members between January and December 2021
After the methyl radical is released, one electron is transferred to the cobalamin particle